Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
NEW YORK (Reuters Health) – A review of the literature has shown that the most important harms from cancer screening are often not quantified in screening trials. “Healthcare…
NEW YORK (Reuters Health) – A Dutch population-based study has shown that, while mucinous colorectal cancer is thought to carry a poor prognosis, it actually responds as well…
NEW YORK (Reuters Health) – Ten-year follow-up data from two UK trials confirm that a lower total dose of radiotherapy delivered in fewer, larger fractions is at least…
The switch to Electronic Health Records (EHR) is one that seems painful to the healthcare provider, as it suggests increased documentation time and increased work load. Dan Riskin,…
With flu season approaching, doctors recommend that people get a flu shot. Past studies suggest that the vaccine may help protect heart patients from heart attack, stroke and…
Clara Knappertz gives a comprehensive report on multiple sclerosis including the definition, symptoms, causes, and current treatments. She also explains the etymology of the name, the history of…
Atul J. Butte, Chief of the Division of Systems Medicine at Stanford University School of Medicine, explains why it’s an amazing time right now for biomedical research. As…
NEW YORK (Reuters Health) – A European study indicates that starting with endosonography for assessing mediastinal lymph node status in potentially resectable lung cancer is more cost-effective than…
Larry Smarr, Founding Director, CALIT2, details the growing epidemic of children, especially those with gastrointestinal disorders, who were not exposed to the necessary microbiomes during the formative years…
NEW YORK (Reuters Health) – The combination of pomalidomide and low-dose dexamethasone improves survival in patients with advanced multiple myeloma more than does treatment with high-dose dexamethasone alone,…
